rawfin.tv
TrivarX Advances Stabl-Im Safety Trial with Beyond Drug Development
TechnologystocksAI Generated

TrivarX Advances Stabl-Im Safety Trial with Beyond Drug Development

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

TrivarX has engaged Beyond Drug Development to progress its Stabl-Im Phase 1 safety trial, targeting a second-half 2026 start. The company aims to gather crucial data for regulatory submissions.

TrivarXBiotechDrug DevelopmentClinical TrialsHealthcare

Related Articles

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

stocks
S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks